Superworth

Moleculin Biotech free cash flow MBRX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2016.

Last 12 months, to Dec 31, 2025
−$22.7M
Latest quarter, Q4 FY25
−$5.4M
Fiscal year 2025
−$22.7M

Moleculin Biotech's free cash flow was −$22.7M over the twelve months to Dec 31, 2025.

In its latest quarter, Q4 FY25, it was −$5.4M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$22.7Mn/a
FY2024−$23.9Mn/a
FY2023−$24.2Mn/a
FY2022−$27.7Mn/a
FY2021−$19Mn/a
FY2020−$18.1Mn/a
FY2019−$17.3Mn/a
FY2018−$12.6Mn/a
FY2017−$7.4Mn/a
FY2016n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY25−$5.4Mn/a−$22.7M
Q3 FY25−$7.2Mn/a−$22.5M
Q2 FY25−$5.6Mn/a−$21.3M
Q1 FY25−$4.6Mn/a−$21.7M
Q4 FY24−$5.1Mn/a−$23.9M
Q3 FY24−$6.1Mn/a−$24.3M
Q2 FY24−$6Mn/a−$25.7M
Q1 FY24−$6.7Mn/a−$24.9M
Q4 FY23−$5.5Mn/a−$24.2M
Q3 FY23−$7.6Mn/a−$26M
Q2 FY23−$5.1Mn/a−$26M
Q1 FY23−$6Mn/a−$28.9M

Against its peers

Companies in Healthcare nearest Moleculin Biotech's size, closest first, today.

CompanyFree cash flow yield
MBRXMoleculin Biotechn/m
NEPHNephrosn/m
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech10.3%
Peer median10.3%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Moleculin Biotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.